Registro Español de Diálisis y Trasplante (REDYT): informe del año 2023 y análisis evolutivo.

Saved in:

Bibliographic Details
Title:	Registro Español de Diálisis y Trasplante (REDYT): informe del año 2023 y análisis evolutivo.
Alternate Title:	Spanish Registry of Dialysis and Transplantation: 2023 Report and evolutive analysis.
Authors:	Quiroga, Borja^1,2,3, Mahíllo, Beatriz⁴, Mazuecos, Auxiliadora^5,6, Ortiz, Alberto^3,7,8, Troya Saborido, Maribel⁹, Hernández Marrero, Domingo^10,11, Trujillo Alemán, Sara¹², Santiuste, Carmen^13,14, Rodríguez Arévalo, Olga Lucía¹⁵, Marques Vidas, María^3,16, Slon-Roblero, María Fernanda¹⁷, Artamendi Larrañaga, Marta¹⁸, Moina Eguren, Iñigo¹⁹, Valentín Muñoz, María de la Oliva²⁰, Moreno Alia, Inmaculada²¹, Bouzas Caamaño, M. Encarnación²², Blanco Galán, M. Antonia²³, Deira Lorenzo, Javier²⁴, Hernández Ramírez, Sara²⁵, Arribas Monzon, Federico Eduardo²⁶
Source:	Nefrologia. May2026, Vol. 46 Issue 5, p1-14. 14p.
Subjects:	RENAL replacement therapy, KIDNEY transplantation, SPANIARDS, CHRONIC kidney failure, PUBLIC health, DEATH rate, HEMODIALYSIS, EPIDEMIOLOGY
Geographic Terms:	SPAIN
Abstract (English):	Introduction: Chronic kidney disease (CKD) will be the second leading cause of death worldwide by 2100. The Spanish Dialysis and Transplantation Registry (REDYT) records the incidence, prevalence and mortality of all patients requiring renal replacement therapy (RRT) in Spain. This article focuses on the 2023 report. Methods: Data are provided by Spanish autonomous regions and cities and the Organizacioń Nacional de Trasplantes. Incidence and prevalence rates of RRT have been calculated (considering the Spanish population according to annual data from the Instituto Nacional de Estadística), as well as mortality of patients on RRT in our country during the period 2014-2023. Results: The incidence rate of RRT has increased by 15% over the last decade, reaching 153.7 persons per million people (pmp) in 2023, with 76.6% corresponding to haemodialysis (HD), 16.9% to peritoneal dialysis (PD), and 6.5% to kidney transplantation. Diabetes is the leading cause of CKD requiring RRT (25.2%). The incidence rate of RRT was more than twice as high in men as in women, with large differences among autonomous communities. The prevalence rate of RRT in 2023 was 1,404.8 pmp, showing a progressive increase over the last decade, mainly due to a rise in the kidney-transplanted population (55.8%). There was an over 2-fold difference between communities in the transplant/dialysis prevalence ratio (1.93 to 0.77, state average 1.26). In 2023, Spain performed 3,690 kidney transplants (76.8 pmp), maintaining the country’s position as a global leader. Donation came mainly from brain death donors (47.9%), followed by donation after circulatory death donors (40.3%) and living donors (11.8%). There was a 10-fold difference between communities in the living donor/deceased donor ratio (0.21 to 0.02, state average 0.13). The overall annual mortality of patients on RRT returned to pre-pandemic levels at 7.4% (13.3% in HD, 8.5% in PD and 2.6% in transplantation. Conclusions: The incidence and prevalence of patients on RRT continues to increase in Spain, albeit with significant variation between autonomous communities. Annual mortality returned to pre-pandemic levels after 3 years. Nevertheless, public health measures are required to slow CKD progression and promote equity in Spain. [ABSTRACT FROM AUTHOR]
Abstract (Spanish):	Introducción La enfermedad renal crónica (ERC) será la segunda causa de muerte en el mundo en 2100. El Registro Español de Diálisis y Trasplante (REDYT) recopila información sobre la incidencia, la prevalencia y la mortalidad de todos los pacientes con ERC en terapia renal sustitutiva (TRS) en España. La presente publicación se centra en el Informe del año 2023. Métodos Los datos del REDYT proceden de los remitidos por las comunidades autónomas (CC. AA.) y las ciudades autónomas, así como los aportados por la Organización Nacional de Trasplantes. Se ha calculado la incidencia y la prevalencia de la TRS (atendiendo a la población española conforme a los datos anuales del Instituto Nacional de Estadística) y la mortalidad de los pacientes en TRS en nuestro país durante el periodo 2014-2023. Resultados La tasa de incidencia de TRS ha crecido en la última década un 15% siendo de 153,6 personas por millón (pmp) en 2023, correspondiendo un 76,6% a hemodiálisis (HD), un 16,9% a diálisis peritoneal (DP) y un 6,5% a trasplante renal. La diabetes es la primera causa de ERC con necesidad de TRS (25,2%). La tasa de incidencia de TRS fue más de 2 veces mayor en los varones que en las mujeres, con grandes diferencias entre CC. AA. La tasa de prevalencia de TRS del año 2023 fue de 1.404,8 pmp, con un ascenso del 16,1% en la última década, principalmente a expensas de un aumento en la población trasplantada renal (55,8%). Hubo grandes diferencias entre comunidades en la relación entre prevalencia de trasplante y prevalencia de diálisis (entre 1,93 y 0,77, media estatal: 1,26). En el año 2023, se realizaron 3.690 trasplantes renales en España (76,8 pmp), que mantiene el liderazgo mundial. La donación procede principalmente de la muerte encefálica (47,9%), seguida de la donación en asistolia (40,3%) y la donación de vivo (11,8%). Hubo grandes diferencias entre comunidades en la relación entre donante vivo y donante cadáver (entre 0,21 y 0,02, media estatal: 0,13). La mortalidad global de los pacientes en TRS retornó a niveles prepandemia: 7,4% anual (13,3% en HD, 8,5% en DP y 2,6% en trasplante). Conclusiones La incidencia y la prevalencia de los pacientes en TRS sigue en aumento en España, aunque con una amplia variabilidad entre CC. AA. La mortalidad retornó a niveles prepandemia 3 años después. Se precisan de medidas de salud pública que permitan enlentecer la progresión de la ERC en España y mejorar la equidad. [ABSTRACT FROM AUTHOR]
	Copyright of Nefrologia is the property of Revista Nefrologia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	MedicLatina

Description
Abstract:	Introduction: Chronic kidney disease (CKD) will be the second leading cause of death worldwide by 2100. The Spanish Dialysis and Transplantation Registry (REDYT) records the incidence, prevalence and mortality of all patients requiring renal replacement therapy (RRT) in Spain. This article focuses on the 2023 report. Methods: Data are provided by Spanish autonomous regions and cities and the Organizacioń Nacional de Trasplantes. Incidence and prevalence rates of RRT have been calculated (considering the Spanish population according to annual data from the Instituto Nacional de Estadística), as well as mortality of patients on RRT in our country during the period 2014-2023. Results: The incidence rate of RRT has increased by 15% over the last decade, reaching 153.7 persons per million people (pmp) in 2023, with 76.6% corresponding to haemodialysis (HD), 16.9% to peritoneal dialysis (PD), and 6.5% to kidney transplantation. Diabetes is the leading cause of CKD requiring RRT (25.2%). The incidence rate of RRT was more than twice as high in men as in women, with large differences among autonomous communities. The prevalence rate of RRT in 2023 was 1,404.8 pmp, showing a progressive increase over the last decade, mainly due to a rise in the kidney-transplanted population (55.8%). There was an over 2-fold difference between communities in the transplant/dialysis prevalence ratio (1.93 to 0.77, state average 1.26). In 2023, Spain performed 3,690 kidney transplants (76.8 pmp), maintaining the country’s position as a global leader. Donation came mainly from brain death donors (47.9%), followed by donation after circulatory death donors (40.3%) and living donors (11.8%). There was a 10-fold difference between communities in the living donor/deceased donor ratio (0.21 to 0.02, state average 0.13). The overall annual mortality of patients on RRT returned to pre-pandemic levels at 7.4% (13.3% in HD, 8.5% in PD and 2.6% in transplantation. Conclusions: The incidence and prevalence of patients on RRT continues to increase in Spain, albeit with significant variation between autonomous communities. Annual mortality returned to pre-pandemic levels after 3 years. Nevertheless, public health measures are required to slow CKD progression and promote equity in Spain. [ABSTRACT FROM AUTHOR]
ISSN:	02116995
DOI:	10.1016/j.nefro.2026.501510